- Home
- EKSO
as of 02-27-2026 3:56pm EST
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN RAFAEL |
| Market Cap: | 37.9M | IPO Year: | 2012 |
| Target Price: | $9.50 | AVG Volume (30 days): | 154.8K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.91 | EPS Growth: | 41.76 |
| 52 Week Low/High: | $0.23 - $13.27 | Next Earning Date: | 05-18-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 81.23% | Revenue Growth (next year): | 7.29% |
| P/E Ratio: | -2.06 | Index: | N/A |
| Free Cash Flow: | -11989000.0 | FCF Growth: | N/A |
AI-Powered EKSO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ekso Bionics Holdings Inc. (EKSO)
10% Owner
Avg Cost/Share
$10.95
Shares
16,740
Total Value
$202,682.20
Owned After
270,432
10% Owner
Avg Cost/Share
$9.05
Shares
27,192
Total Value
$245,686.76
Owned After
270,432
10% Owner
Avg Cost/Share
$9.44
Shares
39,032
Total Value
$373,655.95
Owned After
270,432
10% Owner
Avg Cost/Share
$9.69
Shares
20,611
Total Value
$199,770.06
Owned After
270,432
SEC Form 4
10% Owner
Avg Cost/Share
$9.92
Shares
10,200
Total Value
$101,224.80
Owned After
270,432
SEC Form 4
10% Owner
Avg Cost/Share
$9.96
Shares
4,800
Total Value
$47,820.00
Owned After
270,432
SEC Form 4
10% Owner
Avg Cost/Share
$9.86
Shares
194
Total Value
$1,911.91
Owned After
270,432
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$9.25
Shares
1,320
Total Value
$12,210.00
Owned After
25,621
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.70
Shares
1,238
Total Value
$5,818.60
Owned After
24,771
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$4.70
Shares
270
Total Value
$1,269.00
Owned After
25,621
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ASHER DANIEL | EKSO | 10% Owner | Feb 19, 2026 | Buy | $10.95 | 16,740 | $202,682.20 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 13, 2026 | Buy | $9.05 | 27,192 | $245,686.76 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 12, 2026 | Buy | $9.44 | 39,032 | $373,655.95 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 11, 2026 | Buy | $9.69 | 20,611 | $199,770.06 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 10, 2026 | Buy | $9.92 | 10,200 | $101,224.80 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 9, 2026 | Buy | $9.96 | 4,800 | $47,820.00 | 270,432 | |
| ASHER DANIEL | EKSO | 10% Owner | Feb 6, 2026 | Buy | $9.86 | 194 | $1,911.91 | 270,432 | |
| Jones Jason C | EKSO | Chief Operating Officer | Jan 6, 2026 | Sell | $9.25 | 1,320 | $12,210.00 | 25,621 | |
| Wong Jerome | EKSO | Chief Financial Officer | Dec 9, 2025 | Sell | $4.70 | 1,238 | $5,818.60 | 24,771 | |
| Jones Jason C | EKSO | Chief Operating Officer | Dec 9, 2025 | Sell | $4.70 | 270 | $1,269.00 | 25,621 |
Compare EKSO vs Leading Stocks
See how EKSO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EKSO Ekso Bionics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.